By Kuldip K. Ambastha and Anil K. Ambastha
Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in the marketplace for dementia-related psychosis, a huge market segment. Acadia’s Phase 3 HARMONY study has been been stopped early since strongly positive results have been seen for using Nuplazid in relation to dementia-related psychosis. Acadia’s stock rose by 63% on Monday, September 9, plus another 6% on Tuesday, September 10. Intraday on Monday, Acadia’s stock reached its 52-week high of $43.98 per share and is trading at close to its 4-year high. Eventually, Acadia will seek FDA approval to allow people to buy Nuplazid for dementia-related psychosis.
Keywords – Acadia Pharmaceuticals Inc., ACAD, Nuplazid, pimavanserin, Parkinson’s disease, dementia, psychosis, FDA, health, wellness, pharmaceutical, biopharmaceutical, healthcare.
Disclosure – The principals of Ambastha Financial LLC have no position in ACAD.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2019 – Ambastha Financial LLC.